In vitro contracture test and gene typing in diagnosing malignant hyperthermia

被引:0
|
作者
Rüffert, H
Olthoff, D
Deutrich, C
Thamm, B
Froster, U
机构
[1] Univ Leipzig, Bereich Med, Klin & Poliklin Anasthesiol & Intens Therapie, D-04103 Leipzig, Germany
[2] Univ Leipzig, Inst Humangenet, Leipzig, Germany
来源
ANAESTHESIST | 2000年 / 49卷 / 02期
关键词
malignant hyperthermia; MH-diagnosis; genotyping; in vitro contracture test;
D O I
10.1007/s001010050017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Malignant hyperthermia (MH) is an autosomal dominantly inherited disorder,triggered in susceptible individuals by inhalation anesthetics and depolarizing muscle relaxants such as succinylcholine. Because of its high sensitivity (97-99%) and specificity (93,6%) as well as the genetic heterogeneity of MH disorder, the in vitro contracture test (IVCT) following the European-MH-Group is considered to be the "Gold Standard" for phenotypical determination of predisposed patients. On the other hand mutations in the skeletal muscle ryanodine receptor gene (RYR1) are tightly linked with MH susceptibility. After detecting a C1840T-mutation (Arg614Cys) in the RYR1 gene in one individual of a large MH family, we searched far this mutation in the remaining family members and determined the concordance with IVCT. Methods: According to the European standard protocol for MH, 43 individuals of a large MH pedigree were assigned the status of MH susceptible (MHS), - negative (MHN) or - equivocal (MHE). The genetic investigation of 44 family members for the Arg614Cys-mutation was carried out by restriction fragment analysis:Genomic DNA was prepared from EDTA whole blood followed by amplification of a 918 bp RYR1 gene fragment by polymerase chain reaction. In presence of the Arg614Cys-mutation digestion with the restriction endonuclease RsaI would result in different DNA fragments of the amplified sequence than in absence of mutation. Results: According to the response to IVCT, 25 individuals phenotypically revealed MHS, 7 MHE and 11 MHN status. Out of the 44 family members screened genetically for the Arg614Cys-mutation, the mutation was detected in 23 individuals. Out of them 19 were MHS and one was MHEc. The mutation was absent in 9 predisposed individuals, but six of them were MHE and three MHS. The mutation was also present in three individuals who had no MH screening (IVCT) before. For these last mentioned individuals the diagnosis MHS was deduced from genetic results. Conclusion: Based on results of IVCT the identification of a MH associated mutation in a MH-family can make and support a correct MH diagnosis and can resolve MHE findings.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [21] 4-Chloro-m-Cresol in vitro contracture test in patients suspicious for malignant hyperthermia and control individuals
    Weisshorn, R
    Wappler, F
    Scholz, J
    Fiege, M
    Esch, JSA
    [J]. ANESTHESIOLOGY, 2000, 93 (3A) : U163 - U163
  • [22] CONTRACTURE TESTING FOR MALIGNANT HYPERTHERMIA (MH)
    ROSENBERG, H
    FLETCHER, J
    [J]. MUSCLE & NERVE, 1986, 9 (05) : 223 - 223
  • [23] Multiminicores in malignant hyperthermia : Histological, in vitro contracture tests and genetic characterization.
    Guis, S
    Figarella-Branger, D
    Monnier, N
    Bendahan, D
    Kozak-Ribbens, G
    Mattei, JP
    Lunardi, J
    Cozzone, PJ
    Pellissier, JFO
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S105 - S105
  • [24] In vitro muscle contracture investigations on the malignant hyperthermia like episodes in myotonia congenita
    Hoppe, K.
    Lehmann-Horn, F.
    Chaiklieng, S.
    Jurkat-Rott, K.
    Adolph, O.
    Klingler, W.
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2013, 57 (08) : 1017 - 1023
  • [25] In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
    Metterlein, Thomas
    Schuster, Frank
    Kranke, Peter
    Roewer, Norbert
    Anetseder, Martin
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2011, 28 (04) : 251 - 255
  • [26] Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands
    Islander, G
    Bendixen, D
    RanklevTwetman, E
    Ording, H
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1996, 40 (05) : 579 - 584
  • [27] Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil
    Sudo, R. T.
    Cunha, L. B. P.
    Carmo, P. L.
    Matos, A. R.
    Trachez, M. M.
    Cardoso, L. A. M.
    Aguiar, M. I. S.
    Abreu, A. V.
    Zapata-Sudo, G.
    [J]. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2010, 43 (06) : 549 - 556
  • [28] DIAGNOSING MALIGNANT HYPERTHERMIA SUSCEPTIBILITY
    HOPKINS, PM
    HALSALL, PJ
    ELLIS, FR
    [J]. ANAESTHESIA, 1994, 49 (05) : 373 - 375
  • [29] Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil
    Almeida da Silva, Helga Cristina
    Ferreira, Gisele
    Rodrigues, Gislene
    dos Santos, Joilson Moura
    Andrade, Pamela Vieira
    Hortense, Alexandre
    Perez, Marcelo Vaz
    Gomes do Amaral, Jose Luiz
    [J]. REVISTA BRASILEIRA DE ANESTESIOLOGIA, 2019, 69 (02): : 152 - 159
  • [30] Results of in vitro contracture tests for the diagnosis of malignant hyperthermia susceptibility in monozygote twins
    Islander, G
    Twetman, ER
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1997, 41 (06) : 731 - 735